Little interest from pharma in US FDA's drug naming pilot programme
This article was originally published in SRA
A two-year, US Food and Drug Administration pilot programme to find the best model for evaluating proposed proprietary names for medicines has drawn a poor response from the pharmaceutical industry1-3.
You may also be interested in...
After agreeing on an EU-wide harmonized approach to deal with nitrosamine contamination in medicines, a recently formed regulatory oversight group has identified several topics requiring further scientific discussion.
After preliminary discussions with its pandemic task force, the European Medicines Agency has begun reviewing GSK/Vir Biotechnology’s promising COVID-19 treatment to help EU national competent authorities make evidence-based decisions on its possible early use.
Coronavirus Notebook: New EMA Review To Contextualize Blood Clot Risk From AZ Jab, EU Gets Earlier Access To More Pfizer Vaccines
Denmark has stopped using the AstraZeneca vaccine completely, while the Canadian regulator is not recommending restrictions in any specific populations. Can a new EMA review provide better context to guide the vaccine’s use in different age groups and gender?